Drug Profile
NW 1048
Latest Information Update: 19 Jan 2007
Price :
$50
*
At a glance
- Originator Newron Pharmaceuticals
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Parkinson's disease
Most Recent Events
- 26 Sep 2001 Preclinical development for Parkinson's disease in Italy (PO)
- 06 Dec 2000 Preclinical development for Parkinson's disease in Italy (Unknown route)